BridgeMD
New treatment option for Primary Aldosteronism
Official title Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism
ClinicalTrials.gov ID: NCT06773663
What this study is testing
What is Al18F-NOTA-Pentixafor PET/CT?
Al18F-NOTA-Pentixafor PET/CT is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for primary aldosteronism.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-Pentixafor PET imaging in patients with primary aldosteronism. And evaluates the potential of Al18F-NOTA-Pentixafor PET imaging in surgical strategy guidance.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Patients with adrenal masses suspected to be aldosterone-producing adenomas based on routine imaging (e.g., CT scans), or clinically diagnosed...
- Signed written informed consent, with willingness and ability to comply with study procedures.
- Female participants must be surgically sterilized or postmenopausal for over a year; if not, reliable contraception is required.
- Male participants must use reliable contraception during the study and refrain from sperm donation.
You likely can't join if
- Severe neurological disorders, or any significant diseases affecting the gastrointestinal, cardiovascular, hepatic, renal, hematological...
- Diagnosis of claustrophobia.
- History of drug abuse or alcohol dependence.
- Pregnant or breastfeeding women.
- Poor venous access that would preclude repeated venipuncture.
- Use of experimental drugs or devices within one month prior to the study, where the safety or how well it works has not been established.
See the full eligibility criteria
- Patients with adrenal masses suspected to be aldosterone-producing adenomas based on routine imaging (e.g., CT scans), or clinically diagnosed primary aldosteronism patients requiring subtyping
- Signed written informed consent, with willingness and ability to comply with study procedures.
- Female participants must be surgically sterilized or postmenopausal for over a year; if not, reliable contraception is required.
- Male participants must use reliable contraception during the study and refrain from sperm donation.
- Severe neurological disorders, or any significant diseases affecting the gastrointestinal, cardiovascular, hepatic, renal, hematological, oncological, endocrine, respiratory, or immune systems, or other serious...
- Diagnosis of claustrophobia.
- History of drug abuse or alcohol dependence.
- Pregnant or breastfeeding women.
- Poor venous access that would preclude repeated venipuncture.
- Use of experimental drugs or devices within one month prior to the study, where the safety or how well it works has not been established.
- Any condition that the study investigators deem could pose potential harm or jeopardize participant safety.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.